<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5344902</article-id><article-id pub-id-type="doi">10.3389/fimmu.2017.00259</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Type I Interferons as Regulators of Lung Inflammation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Makris</surname><given-names>Spyridon</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/401163"/></contrib><contrib contrib-type="author"><name><surname>Paulsen</surname><given-names>Michelle</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>&#x02020;</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/401172"/></contrib><contrib contrib-type="author"><name><surname>Johansson</surname><given-names>Cecilia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/299141"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Section of Respiratory Infections, National Heart and Lung Institute, Imperial College London</institution>, <addr-line>London</addr-line>, <country>UK</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Claudia U. Duerr, McGill University, Canada</p></fn><fn fn-type="edited-by"><p>Reviewed by: Sabine Riffault, Centre de Recherches de Jouy-en-Josas (INRA), France; Andreas Wack, Francis Crick Institute, UK</p></fn><corresp content-type="corresp" id="cor1">*Correspondence: Cecilia Johansson, <email>c.johansson@imperial.ac.uk</email></corresp><fn fn-type="present-address" id="fn001"><p><sup>&#x02020;</sup>Present address: Michelle Paulsen, Department of Translational Pulmonology, Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), University of Heidelberg, Germany</p></fn><fn fn-type="other" id="fn002"><p>Specialty section: This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>10</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>8</volume><elocation-id>259</elocation-id><history><date date-type="received"><day>21</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>21</day><month>2</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 Makris, Paulsen and Johansson.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Makris, Paulsen and Johansson</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Immune responses to lung infections must be tightly regulated in order to permit pathogen eradication while maintaining organ function. Exuberant or dysregulated inflammation can impair gas exchange and underlies many instances of lung disease. An important driver of inflammation in the lung is the interferon (IFN) response. Type I IFNs are antiviral cytokines that induce a large range of proteins that impair viral replication in infected cells. This cell-intrinsic action plays a crucial role in protecting the lungs from spread of respiratory viruses. However, type I IFNs have also recently been found to be central to the initiation of lung inflammatory responses, by inducing recruitment and activation of immune cells. This helps control virus burden but can cause detrimental immunopathology and contribute to disease severity. Furthermore, there is now increasing evidence that type I IFNs are not only induced after viral infections but also after infection with bacteria and fungi. The pro-inflammatory function of type I IFNs in the lung opens up the possibility of immune modulation directed against this antiviral cytokine family. In this review, the initiation and signaling of type I IFNs as well as their role in driving and maintaining lung inflammation will be discussed.</p></abstract><kwd-group><kwd>lung</kwd><kwd>infection</kwd><kwd>inflammation</kwd><kwd>type I interferons</kwd><kwd>pattern recognition receptors</kwd></kwd-group><funding-group><award-group><funding-source id="cn01">Medical Research Council<named-content content-type="fundref-id">10.13039/501100000265</named-content></funding-source><award-id rid="cn01">G0800311</award-id></award-group><award-group><funding-source id="cn02">Rosetrees Trust<named-content content-type="fundref-id">10.13039/501100000833</named-content></funding-source><award-id rid="cn02">M370</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="0"/><equation-count count="0"/><ref-count count="113"/><page-count count="10"/><word-count count="8224"/></counts></article-meta></front><body><sec id="S1"><title>Lung Inflammation</title><p>Mucosal surfaces such as those found in the intestine and the lungs are the most common targets for invading pathogens. The surface area of the human lung is approximately 70&#x02009;m<sup>2</sup>, and its main function is gas exchange (<xref rid="B1" ref-type="bibr">1</xref>). The lung is constantly in direct contact with the environment and the cells of the lung need to be able to tolerate non-harmful stimuli but react appropriately to harmful pathogens. When lung cells respond to invading pathogens, the regulation of inflammation is particularly important since the lung comprises delicate structure crucial for conducting gas exchange.</p><p>Interferons (IFNs), discovered in the 1950s, represent a family of cytokines, which induce robust antiviral and immunomodulatory responses to interfere with virus replication and spread (<xref rid="B2" ref-type="bibr">2</xref>&#x02013;<xref rid="B4" ref-type="bibr">4</xref>). IFNs can be classified into three main subclasses: type I, II, and III. Type I IFNs consist of several IFN-&#x003b1; isoforms (13 in human and 14 in mice), IFN-&#x003b2;, IFN-&#x0025b;, IFN-&#x003ba;, and IFN-&#x003c9;. In contrast, type II IFNs include only one member, IFN-&#x003b3;. The most recently discovered group of IFNs are the type III IFNs, including IFN-&#x003bb;1 (IL-29; non-functional pseudogene in mice), IFN-&#x003bb;2 (IL-28A), IFN-&#x003bb;3 (IL-28B), and the very recently described human IFN-&#x003bb;4 (<xref rid="B5" ref-type="bibr">5</xref>&#x02013;<xref rid="B7" ref-type="bibr">7</xref>). This review will focus on the role of type I IFNs in the lung, however, many of the effects induced by type I IFNs will also be mediated by the other types of IFNs.</p><p>Sensing of pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs) results in production of many cytokines and chemokines including the type I IFNs. These cytokines have a whole array of functions. First, they elicit an antiviral state in infected and neighboring, uninfected cells. Second, type I IFNs modulate the immune response by promoting antigen presentation, cytokine production, dendritic cell (DC) and natural killer (NK) cell activity, and macrophage function. Third, they enhance the adaptive immune response by manipulating T cell effector function and antibody production. Overall, the antiviral and immune stimulatory potential of type I IFNs is required for the effective clearance of acute viral infections (<xref rid="B2" ref-type="bibr">2</xref>&#x02013;<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B8" ref-type="bibr">8</xref>). Furthermore, the impact of type I IFNs on the inflammatory response during other types of infections is also starting to be appreciated.</p></sec><sec id="S2"><title>Induction of Type I IFNs</title><p>Multiple cell types including leukocytes and structural cells can detect PAMPs, in various cellular compartments and in all tissues. Recognition of PAMPs by the PRRs initiates an intracellular signaling cascade that causes the translocation of transcription factors to the nucleus initiating innate immune gene expression. The PRRs that can couple pathogen detection to type I IFN induction are toll-like receptors (TLRs), retinoic acid-inducible gene I (RIG)-I-like receptors (RLRs), and cGAS/cGAMP/stimulator of IFN genes [stimulator of interferon genes (STING); Figure <xref ref-type="fig" rid="F1">1</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Pattern recognition receptor signaling that leads to the induction of type I interferons (IFNs)</bold>. The endosomally expressed TLR-3, -7, -8, and -9, cell surface expressed TLR4, the RLRs [retinoic acid-inducible gene I (RIG)-I and MDA-5], and cGAMP synthase (cGAS) can couple pathogen detection to type I IFN induction. TLR3 and TLR4 signal <italic>via</italic> TRIF, which occurs through inhibitor of kappa-B (I&#x003ba;B) kinases (IKKs), tumor necrosis factor (TNF) receptor-associated factor (TRAF) family associated NF-&#x003ba;B activator (TANK)-binding kinase-1 (TBK1), and IKK-&#x0025b;. This causes the activation of IRF3, which in turn induces the expression of type I IFNs. The activation of TLR3 can also induce the production of inflammatory mediators <italic>via</italic> TRIF by activating a complex formed by TRAF-6, TNF receptor type I DEATH domain-associated protein (TRADD), Pellino-1, and the receptor-interacting kinase (RIP)-1. This causes the activation of NF-&#x003ba;B pathway, which is mediated by the IKK complex and transforming growth factor beta activated kinase (TAK)-1. TLR7, 8, and 9 use MyD88 for downstream signaling and can activate IRF and NF-&#x003ba;B pathways. RIG-I and MDA5 signal through the adaptor molecule mitochondrial antiviral signaling protein (MAVS). cGAS signals <italic>via</italic> the adaptor protein stimulator of interferon genes (STING). MAVS and STING further recruit signaling molecules (involving the IKK complex, TBK1, and several TRAF proteins) and lead to the activation of NF-&#x003ba;B and IRF3, resulting in gene expression of various antiviral cytokines including type I IFNs (<xref rid="B9" ref-type="bibr">9</xref>&#x02013;<xref rid="B13" ref-type="bibr">13</xref>).</p></caption><graphic xlink:href="fimmu-08-00259-g001"/></fig><p>The endosomally expressed TLRs that induce type I IFN gene expression are TLR-3, -7, -8, and -9, each of which detects different forms of nucleic acids (<xref rid="B14" ref-type="bibr">14</xref>). TLR3 recognizes double-stranded (ds) RNA which initiates the TRIF-dependent signaling cascade (<xref rid="B15" ref-type="bibr">15</xref>). TLR-7/8 and -9 recognize GU-rich single-stranded (ss) RNA and unmethylated CpG DNA, respectively (<xref rid="B9" ref-type="bibr">9</xref>), and they require MyD88 for their signaling. Finally, one cell surface expressed TLR, TLR4, which recognize lipopolysaccharides (LPS), and respiratory syncytial virus (RSV) F protein (<xref rid="B16" ref-type="bibr">16</xref>), can induce type I IFNs <italic>via</italic> TRIF-mediated signaling (<xref rid="B15" ref-type="bibr">15</xref>) (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><p>The three receptors in the RLRs family, RIG-I, melanoma differentiation-associated protein 5 (MDA5), and laboratory of genetics and physiology 2 (LGP2) detect viral RNA in the cytosol (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). Due to their localization within the cytoplasm, these receptors are constantly exposed to host RNA, and it is therefore important to distinguish it from that of viral origin. For this reason, the receptors can detect features that are common in many viral genomes and viral replication intermediates but absent from the host (<xref rid="B12" ref-type="bibr">12</xref>). RIG-I specifically binds to short uncapped 5&#x02032;-triphosphate (5&#x02032;-ppp) and 5&#x02032;-diphosphate (5&#x02032;-pp)-bearing base-paired RNA molecules, an RNA motif known to be present in some viral genomes but not in host RNA (<xref rid="B17" ref-type="bibr">17</xref>&#x02013;<xref rid="B19" ref-type="bibr">19</xref>). MDA5 binds long stretches of base-paired RNA, which, again, are absent from uninfected cells but often produced as a consequence of viral replication (<xref rid="B11" ref-type="bibr">11</xref>). Structurally, RIG-I and MDA5 share many similarities as they both have caspases activation and recruitment domains (CARDs) essential for the downstream signaling (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). LGP2 possesses the RNA-binding domain but it lacks the CARD domains and is therefore not involved in direct signaling. Instead, a role for LGP2 in assisting MDA5-mediated signaling has been suggested (<xref rid="B20" ref-type="bibr">20</xref>). For both RIG-I and MDA5, binding of agonists allows downstream signaling through the adaptor molecule mitochondrial antiviral signaling protein (MAVS), leading to the activation of NF-&#x003ba;B and IRF3 and subsequent induction of gene expression of various antiviral mediators including type I IFNs (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>) (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><p>The first DNA sensor described was DNA-dependent activator of IFN-regulatory factors (DAI), which was shown to induce type I IFNs during <italic>in vitro</italic> infections of fibroblast with either herpes simplex virus 1 or cytomegalovirus (CMV). However, the <italic>in vivo</italic> role for DAI remains unclear (<xref rid="B23" ref-type="bibr">23</xref>). Another pathway of recognizing infections with DNA viruses is <italic>via</italic> RNA polymerase III (PolIII), which transforms DNA into a 5&#x02032;-ppp RNA, the ligand for RIG-I, yet the physiological role of PolIII remains elusive (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). Other proteins belonging to the PYHIN (IFI16; IFN gamma-inducible protein 16, and AIM2; absent in melanoma 2) or DExD/H-box helicase (DDX) protein families were suggested likely DNA sensors, but their specific role <italic>in vivo</italic> is unclear and is being investigated [(<xref rid="B26" ref-type="bibr">26</xref>); for an extensive review about DNA sensing, see Ref. (<xref rid="B24" ref-type="bibr">24</xref>)]. The discovery of the adaptor protein STING identified a pathway crucial for the recognition of foreign dsDNA <italic>in vivo</italic>. Located at the endoplasmic reticulum, STING activates signaling <italic>via</italic> NF-&#x003ba;B and IRF3, resulting in the production of type I IFNs (<xref rid="B27" ref-type="bibr">27</xref>) (Figure <xref ref-type="fig" rid="F1">1</xref>). Recently, guanosine-monophosphate adenosine-monophosphate (cyclic GMP-AMP or cGAMP) synthase (cGAS) was identified as a DNA sensor leading to the downstream activation of STING. cGAS binds dsDNA and catalyzes the synthesis of the second messenger cGAMP from ATP and GTP, which binds to STING and activates the signaling cascade leading to type I IFN production (<xref rid="B28" ref-type="bibr">28</xref>&#x02013;<xref rid="B30" ref-type="bibr">30</xref>). Interestingly, cGAMP can be transferred through gap junctions from infected cell to neighboring cells and thereby spread antiviral immunity (<xref rid="B31" ref-type="bibr">31</xref>).</p><p>Different cells of the lung will respond differently to infections depending on both the tropism of the pathogen (which cells that are infected) and which PRRs that are triggered. Lung epithelial cells are the first and most abundant cell type that will interact with the pathogens, and they have the ability to induce IFN-&#x003b2; production especially after influenza virus infection (<xref rid="B32" ref-type="bibr">32</xref>). In addition, plasmacytoid dendritic cells (pDCs) have a constitutive expression of IRF-7, which make them able to respond rapidly to TLR7 ligation and induce type I IFNs (<xref rid="B33" ref-type="bibr">33</xref>). This is especially important during influenza virus infection (<xref rid="B34" ref-type="bibr">34</xref>). However, during RSV infection, it is the alveolar macrophages (AMs) that are the major source of type I IFNs and they use MAVS-dependent PRRs for sensing the virus (<xref rid="B35" ref-type="bibr">35</xref>). Thus, in the lung as well as on other sites, many different pathogens can be recognized by several sets of PRRs expressed on the cell surface, in endosomes, or in the cytosol by different cell types. In combination, this will result in the induction of type I IFNs and an efficient antiviral response.</p></sec><sec id="S3"><title>Signaling through the Type I IFN Receptor</title><p>Type I IFNs bind to the heterodimeric transmembrane IFN-&#x003b1;/&#x003b2; receptor (IFNAR), which is expressed on all nucleated cells and composed of the two subunits: IFNAR1 and IFNAR2 (<xref rid="B36" ref-type="bibr">36</xref>) (Figure <xref ref-type="fig" rid="F2">2</xref>). <italic>Via</italic> signaling through the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, the induction of several hundreds of interferon stimulated genes (ISGs) is initiated (<xref rid="B36" ref-type="bibr">36</xref>&#x02013;<xref rid="B40" ref-type="bibr">40</xref>) (Figure <xref ref-type="fig" rid="F2">2</xref>). These ISGs interfere with various stages of the viral cycle and change the state of the infected and neighboring cells. Type I IFN signaling also drive the immune response to a number of pathogens by, for example, enhancing the production of inflammatory mediators, cell communication, and the induction of apoptosis in infected cells (see below). It is interesting that the type I IFN receptor has so many ligands, and it is still unclear if all type I IFNs bind the receptor in the same way or if binding of certain IFNs results in a functional difference. There is evidence that different IFNs bind to different anchor points resulting in variations to the binding affinities and conformational change of the IFNAR1 (<xref rid="B41" ref-type="bibr">41</xref>). In addition, IFN-&#x003b2; can ligate only the subunit IFNAR1 and signal independently of JAK&#x02013;STAT pathways (<xref rid="B42" ref-type="bibr">42</xref>). Type I IFN production and signaling are tightly regulated by a positive feedback loop, with early IFNs (in the mouse IFN-&#x003b2; and IFN-&#x003b1;4) stimulating the expression of the ISG IRF7 and other important signaling molecules (<xref rid="B43" ref-type="bibr">43</xref>). This regulates the expression of all IFN-&#x003b1; isotypes (<xref rid="B44" ref-type="bibr">44</xref>) resulting in enhanced signaling through the type I IFN receptor (Figure <xref ref-type="fig" rid="F2">2</xref>). While the positive feedback loop is important for enhancing the production and effect of type I IFNs, equally important are the negative regulators that are required to restore cellular homeostasis. The type I IFN response is tightly controlled by a series of mechanism that are dependent on cell-intrinsic factors, ISG-mediated proteins, and miRNA. The activity of STAT proteins can be regulated by protein inhibitors of activated STAT (PIAS) and the suppressor of cytokine proteins (SOCS). Another important ISG for the regulation of type I IFN signaling is the ubiquitin carbol-terminal hydrolase protein, USP18 (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B45" ref-type="bibr">45</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Type I interferon (IFN) signaling</bold>. Type I IFNs bind to the heterodimeric transmembrane IFN-&#x003b1;/&#x003b2; receptor (IFNAR), which is composed of the two subunits: IFNAR1 and IFNAR2. The c-termini of IFNAR1 and IFNAR2 are associated with the tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1), respectively, and activation of the receptor transduces the phosphorylation of JAK1 and TYK2 by tyrosine phosphorylation. This initiates a signaling cascade composed of proteins of the signal transducer and activator of transcription (STAT) family. The STAT1 and STAT2 proteins are activated upon JAK1 phosphorylation, dimerize and together with IRF9, form the ISG factor 3 (ISGF3) complex. This complex translocates to the nucleus and binds to IFN-stimulated response elements (ISREs) in interferon-stimulated genes (ISGs) promoters to initiate gene transcription. Signaling through IFNAR can also occur independent of IRF9 recruitment through STAT1 homodimers that can bind to IFN-&#x003b3;-activated sites (GAS) in ISG promoters. Both pathways initiate transcription that promotes the induction of a range of pro-inflammatory mediators and enhance the antiviral state. The JAK&#x02013;TYK signaling pathway can also promote signaling pathways independent of STAT signaling. One such pathway includes MAPKs, which are important for signals regulating important cellular functions such as gene transcription, post-transcription, apoptosis, and cell-cycle progression. Specifically, the p38 signaling cascade after IFN-stimulation drives transcription of genes that are important for inducing the antiviral effects of type I IFNs and are regulated by ISREs and GAS. Further to MAPK, the type I IFN receptor signaling can also activate the phosphoinositide 3-kinase (PI3K) signaling pathway. The phosphorylation of PI3K causes the activation of the RAC-&#x003b1; serine/threonine-protein kinase (AKT1)/cAMP responsive-element-binding protein that can bind smad binding elements (SBE). This signaling pathway is believed to be important for transcription of genes controlling cellular survival and inflammatory (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B38" ref-type="bibr">38</xref>&#x02013;<xref rid="B40" ref-type="bibr">40</xref>).</p></caption><graphic xlink:href="fimmu-08-00259-g002"/></fig><p>Type I IFN responses are difficult to study in humans since by the time patients with severe lower respiratory tract infections are likely to be admitted to hospital several days have passed since the initial infection, at which time the production of type I IFNs is declining and not easily detectable. However, it is interesting that complete type I IFN deficiency has not been described in humans but mutations in STAT1, tyrosine kinase 2, or NEMO are associated with poor control of viral infections (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>). Recently, a mutation in IRF7, leading to impaired type I and type III IFN responses, was shown to result in severe influenza infection in one case (<xref rid="B48" ref-type="bibr">48</xref>). In addition, severe RSV disease has been associated with polymorphisms in several innate immune response genes, in particular many that control the type I IFN system (<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>). Also, several ISGs have been associated with severe influenza infection in mouse and man, for example, IFITM3 and MX1 (<xref rid="B51" ref-type="bibr">51</xref>&#x02013;<xref rid="B54" ref-type="bibr">54</xref>). Thus, most data suggest an important role for type I IFNs during respiratory infections.</p></sec><sec id="S4"><title>Type I IFNs Driving Lung Inflammation</title><p>The type I IFN signaling is especially important for the control of viral infections. However, in many diseases, the usefulness of type I IFNs has been debated (<xref rid="B55" ref-type="bibr">55</xref>). Like all immune responses, a balance is required and launching a response is as important as dampening it. As type I IFNs can lead to both cellular recruitment and activation, an imbalance of the type I IFN response can influence the cellular responses to either result in immunosuppression or immunopathology.</p><p>Type I IFNs have multiple effects in the lung. They have been shown to result in the production of chemokines such as CCL2, a monocyte chemoattractant, and CXCL10, important for the recruitment of monocytes/macrophages, T cells, NK cells, and DCs, therefore directly influencing inflammation in the lung (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B56" ref-type="bibr">56</xref>&#x02013;<xref rid="B58" ref-type="bibr">58</xref>). The type I IFNs also drive a multitude of events in DCs including the differentiation of precursors, increased antigen presentation and cross-presentation, expression of costimulatory molecules, and promoting chemokine secretion and migration (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B59" ref-type="bibr">59</xref>&#x02013;<xref rid="B66" ref-type="bibr">66</xref>). Interestingly, different subsets of DCs have a different degree of sensitivity to type I IFN signaling, which determines the susceptibility to influenza virus infection and thereby how much antigen they can present (<xref rid="B67" ref-type="bibr">67</xref>). Type I IFNs are also important for the activation of macrophages and NK cells (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B68" ref-type="bibr">68</xref>). Also, CD4<sup>+</sup> and CD8<sup>+</sup> T cells are directly affected by type I IFNs during various infections and the effect of type I IFNs can either be stimulatory or inhibitory by stimulating proliferation, differentiation, survival as well as inducing anti-proliferative and pro-apoptotic responses (<xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B69" ref-type="bibr">69</xref>). Type I IFN receptor signaling in T cells is also important for cytokine secretion, cytotoxicity, and memory formation (<xref rid="B63" ref-type="bibr">63</xref>). This varied effect of type I IFNs on T cells is partly dependent on the different STATs induced by type I IFNs where for example STAT1 is pro-inflammatory, pro-apoptotic, and anti-proliferative, while STAT4 promotes proliferation and cell survival (<xref rid="B63" ref-type="bibr">63</xref>). The different effects are dependent on when and where the T cells get the signal <italic>via</italic> the type I IFN receptor and will therefore be dependent on the site of infection, timing, magnitude, and source of type I IFN responses. B cells are also influenced by type I IFNs, and type I IFN receptor signaling on both B and T cells is important for antibody production (<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B71" ref-type="bibr">71</xref>). Interestingly, it has been suggested that during LCMV infection, type I IFN receptor signaling in CD8<sup>+</sup> T cells increase their killing of B cells and therefore decrease the production of neutralizing antibodies (<xref rid="B72" ref-type="bibr">72</xref>). If this is also occurring during respiratory infections remain to be elucidated.</p><p>In the absence of type I IFNs, there is often less inflammation in the lung. Interestingly, intranasal administration of IFN-&#x003b1; alone can stimulate the expression of pro-inflammatory cytokines (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B73" ref-type="bibr">73</xref>). Also, IFN-&#x003b1; can potentiate the pro-inflammatory responses after intranasal LPS challenge (<xref rid="B56" ref-type="bibr">56</xref>). How this occurs considering most cytokines and chemokines are induced by NF-&#x003ba;&#x003b2; and not IFNAR signaling is unknown. One possibility is the fact that type I IFNs increase the expression of many PRRs or related signaling molecules, which can enhance signaling <italic>via</italic> other pathways for example those involved in NF-&#x003ba;B activation (<xref rid="B74" ref-type="bibr">74</xref>). Nevertheless, all cellular components involved in the mutual influence of NF-&#x003ba;B and type I IFN pathways are not fully investigated and might depend on the cellular context. It is therefore a likely scenario that type I IFNs play a role in NF-&#x003ba;B-induced expression of pro-inflammatory cytokines and chemokines.</p><sec id="S4-1"><title>Lung Viral Infections</title><p>Type I IFNs are rapidly produced during all lung viral infections and contribute to the initial control of viral replication before effective innate and adaptive cellular responses are generated to clear the virus. Signaling <italic>via</italic> the IFNAR activates a cascade of ISGs that directly interfere with viral replication and viral spread. These include proteins that inhibit virus entry (e.g., MX1, IFITM proteins, TRIM proteins), modulate membrane lipids to prevent viral release (e.g., Viperin, Tetherin), induce apoptosis of infected cells [e.g., protein kinase R (PKR)], regulate transcriptional (e.g., Viperin) and posttranscriptional (e.g., OAS/RNaseL, PKR) mechanisms, and posttranslational events (e.g., ISG15) (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B40" ref-type="bibr">40</xref>). In addition to the ISG-mediated effects, type I IFNs modulate cell viability and function (e.g., apoptosis, inhibiting cell death, differentiation, migration, proliferation) to support antiviral defense (<xref rid="B75" ref-type="bibr">75</xref>). The amplification of the primary signal by type I IFNs is achieved by upregulation of many PRR molecules and associated signaling molecules like TLR3, RIG-I, MDA5, MAVS, MyD88, IRF3, and IRF7, which are themselves ISGs and therefore amplify the type I IFN response to viral infections [see above and Ref. (<xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B77" ref-type="bibr">77</xref>)]. Without a functioning IFNAR loop the detection of accumulating viral RNA and the further downstream processing of the signal is compromised in infected cells as they lack the feedback-mediated boosted expression of the viral RNA sensors. This imbalance will eventually promote viral replication and spread early during infection and also influence the degree of inflammation. For example, in a severe acute respiratory syndrome-CoV infection, type I IFN induction is delayed resulting in an overwhelming viral burden (<xref rid="B78" ref-type="bibr">78</xref>). Interestingly, many viruses have virulence factors that antagonize type I IFN responses [reviewed elsewhere (<xref rid="B79" ref-type="bibr">79</xref>&#x02013;<xref rid="B81" ref-type="bibr">81</xref>)], indicating the importance of type I IFN responses during viral infection. It is also important to note that, especially during influenza virus infection, type III IFNs (IFN-&#x003bb;) are highly induced at the same time as type I IFNs (<xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B83" ref-type="bibr">83</xref>). Interestingly, the receptor for IFN-&#x003bb; is mostly expressed by epithelial cells and therefore these cytokines have a more restricted effect directed to intrinsic antiviral mechanisms (<xref rid="B73" ref-type="bibr">73</xref>). The effects of IFN-&#x003bb; have recently been reviewed (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>There are also age-related effects of type I IFN production in response to respiratory infections as both cells from infants and neonatal mice show a reduced type I IFN production and ISG induction after RSV exposure (<xref rid="B84" ref-type="bibr">84</xref>&#x02013;<xref rid="B86" ref-type="bibr">86</xref>). Furthermore, monocytes from elderly have a diminished type I IFN response after exposure to influenza virus (<xref rid="B53" ref-type="bibr">53</xref>). Interestingly, these age groups are also very vulnerable to respiratory infections.</p><p>In addition to the cell-intrinsic responses, type I IFNs are known to enhance immune responses especially by activating and recruiting immune cells. During RSV infection, type I IFNs produced by AMs, induced the production of CCL2 and other chemoattractants crucial for monocyte extravasation into the lung during RSV infection (<xref rid="B35" ref-type="bibr">35</xref>). These recruited monocytes are important for controlling the virus (<xref rid="B35" ref-type="bibr">35</xref>). Interestingly, the expression of pro-inflammatory cytokines and chemokines was significantly reduced in RSV, influenza virus, and human metapneumovirus-infected <italic>Ifnar1<sup>&#x02212;/&#x02212;</sup></italic> mice (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B87" ref-type="bibr">87</xref>, <xref rid="B88" ref-type="bibr">88</xref>). This highlights again a synergizing effect of NF-&#x003ba;B and type I IFN pathways in inducing the optimal secretion of cytokines and chemokines. However, NF-&#x003ba;B translocation into the nucleus can be detected as early as 0.5&#x02009;h post RSV inoculation without the necessity of viral replication (<xref rid="B89" ref-type="bibr">89</xref>). This might provide an explanation for the early induction of some of the measured cytokines such as IFN-&#x003b2;, IL-6, TNF-&#x003b1;, or IL-12 in the lungs of RSV-infected <italic>Ifnar1<sup>&#x02212;/&#x02212;</sup></italic> mice, but perhaps sustained NF-&#x003ba;B activation may be in part type I IFN dependent. In contrast to <italic>Ifnar1<sup>&#x02212;/&#x02212;</sup></italic> mice, wt mice have the ability to further enhance this &#x0201c;first signal&#x0201d; through the IFNAR-driven autocrine and paracrine amplification loop to maximize the responses. Moreover, the lack of responsiveness to viruses in <italic>Ifnar1<sup>&#x02212;/&#x02212;</sup></italic> mice could also suppress the recruitment of additional cells to the site of infection, which could otherwise contribute to local cytokine secretion. These usually specifically recruited cells are most likely of non-polymorphonuclear origin, since neutrophil recruitment was comparable or increased in RSV or influenza virus infected <italic>Ifnar1<sup>&#x02212;/&#x02212;</sup></italic> mice compared to wt mice (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B90" ref-type="bibr">90</xref>). Furthermore, during influenza or Sendai virus infection type I IFNs can act as messengers from the lung to the bone marrow where they instruct leukocytes to activate an antiviral transcriptional program, resulting in an increased antiviral state of these cells before they migrate to the lung (<xref rid="B91" ref-type="bibr">91</xref>).</p><p>Additional to T cell expansion, type I IFNs have been shown to promote T effector cell function due to the dependence on IFNAR mediated STAT1 signaling for the cytolytic activity of memory CD8<sup>+</sup> T cells during recall responses with respiratory viruses (<xref rid="B92" ref-type="bibr">92</xref>). In contrast, after influenza virus infection type I IFNs can induce the secretion of IL-10 from CD8<sup>+</sup> T cells (<xref rid="B93" ref-type="bibr">93</xref>) and the expression of programmed cell death ligand 1 (PDL-1) on epithelial cells (<xref rid="B94" ref-type="bibr">94</xref>). Furthermore, blocking of PDL-1 enhanced CD8<sup>+</sup> T cells function and viral clearance (<xref rid="B94" ref-type="bibr">94</xref>). Thus, type I IFNs are important both to induce T cell effector functions and also to induce anti-inflammatory mechanisms that can suppress the T cell response.</p><p>Despite the essential role for type I IFNs in activating the immune response to successfully combat viral infection and to guarantee survival of the organism, they can have deleterious effects on the host and cause acute immunopathology. High type I IFN production during influenza virus infection mediated by recruited inflammatory monocytes and pDCs cause the upregulation of TNF-related apoptosis-inducing ligand (TRAIL) (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B95" ref-type="bibr">95</xref>). This &#x0201c;death&#x0201d; ligand binds to the death receptor 5 on epithelial cells, the expression of which is also upregulated by type I IFNs. Thus, the TRAIL-expressing inflammatory monocytes cause the death of the epithelial cells, which in turn increases morbidity or death of the mice (<xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B96" ref-type="bibr">96</xref>). Therefore, the potential of type I IFNs to drive and amplify pro-inflammatory responses (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B83" ref-type="bibr">83</xref>) could, if type I IFNs are produced excessively or for an extended time, cause the increased morbidity and mortality during lung viral infections (<xref rid="B78" ref-type="bibr">78</xref>, <xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B96" ref-type="bibr">96</xref>). Thus, the timing and magnitude of type I IFN responses are crucial to obtain an efficient cell-intrinsic response and a balanced cell-extrinsic response that together lead to the clearance of the virus without causing detrimental immunopathology.</p></sec><sec id="S4-2"><title>Lung Bacterial Infections</title><p>Since type I IFNs have an important role in preventing replication and spread during viral infections their role is overall beneficial. During lung bacterial infections, type I IFNs are induced but the role of these cytokines is unclear and their ability to drive inflammation might in these cases be more detrimental. For example, mice deficient in IFNAR1 or TLR9 showed an improved clearance of <italic>Staphylococcus aureus</italic> (<xref rid="B97" ref-type="bibr">97</xref>). Also, a lung infection model of <italic>Chlamydia trachomatis</italic> mouse pneumonitis (<italic>Chlamydia muridarum</italic>) showed that deficiency in the IFNAR1 resulted in less bacterial burden and bodyweight loss, and milder pathological changes (<xref rid="B98" ref-type="bibr">98</xref>). <italic>Mycobacterium tuberculosis</italic> (MTb) infection of TB-susceptible <italic>Ifnar1<sup>&#x02212;/&#x02212;</sup></italic> mice showed enhanced protection from death, lower bacterial burden in the lungs, and decreased degree of lung inflammation compared to wt mice (<xref rid="B99" ref-type="bibr">99</xref>). In addition, an interferon signature is evident in patients with active MTb disease (<xref rid="B100" ref-type="bibr">100</xref>), and mouse studies have shown that the type I IFN responses during MTb infection is tightly regulated by IL-1 and PGE<sub>2</sub> (<xref rid="B101" ref-type="bibr">101</xref>). More contradictory data are presented for <italic>Streptococcus pneumoniae</italic> infection, where an invasive strain of <italic>S. pneumoniae</italic> induces type I IFNs in the lungs and blocking the IFNAR decreased the systemic bacteremia (<xref rid="B102" ref-type="bibr">102</xref>). In contrast, another study showed that <italic>S. pneumoniae</italic> infection of <italic>Ifnar1<sup>&#x02212;/&#x02212;</sup></italic> mice or mice treated with an antibody against the type I IFN receptor displayed enhanced bacterial spread and increase bacteremia (<xref rid="B103" ref-type="bibr">103</xref>). In addition, if mice were given rIFN-&#x003b2;, this reduced the bacteremia after intranasal <italic>S. pneumoniae</italic> infection (<xref rid="B103" ref-type="bibr">103</xref>). Thus, most data suggest that type I IFNs induced during lung bacterial infection are part of the inflammatory response and might be important to initiate immune responses to the infection. However, since these cytokines lead to the recruitment and activation of immune cells, this can enhance inflammation and result in bacterial dissemination and spread.</p><p>Interestingly, bacterial secondary infections are common after a severe lung viral infection and the host is more susceptible to infection by <italic>Escherichia coli, Pseudomonas aeruginosa, S. pneumoniae</italic>, or <italic>S. aureus</italic> after influenza virus infection (<xref rid="B104" ref-type="bibr">104</xref>&#x02013;<xref rid="B106" ref-type="bibr">106</xref>). This increased susceptibility is probably due to many factors such as a lower activation threshold of lung cells, inhibition of important signaling pathways and cytokines induction and exhaustion of immune cells resulting in non-appropriate immune responses elicited to the new pathogen. Noteworthy, this increased susceptibility cease to exist as soon as the virus-induced type I IFNs are decreasing (<xref rid="B104" ref-type="bibr">104</xref>) and IFNAR1 deficient mice can effectively clear a secondary <italic>S. pneumoniae</italic> infection (<xref rid="B106" ref-type="bibr">106</xref>). Furthermore, the induction of type I IFNs during influenza virus infection attenuates chemokines important for neutrophil recruitment, which can promote secondary bacterial pneumonia (<xref rid="B107" ref-type="bibr">107</xref>). A possible mechanism for this is the type I IFN-dependent upregulation of the methyltransferase Setdb2, which can repress chemokines such as CXCL1 at the chromatin level (<xref rid="B108" ref-type="bibr">108</xref>). Also, influenza virus infection before or during MTb infection increases the severity of the MTb infection <italic>via</italic> type I IFN signaling (<xref rid="B109" ref-type="bibr">109</xref>). Interestingly, type I IFNs have been shown to inhibit inflammasome activation and IL-1 responses and increase IL-10 production (<xref rid="B110" ref-type="bibr">110</xref>). Altogether, this suggests that type I elicited during a lung viral infection makes it more possible for a subsequent bacterial infection to establish.</p></sec><sec id="S4-3"><title>Lung Fungal Infections</title><p>The role of type I IFNs during fungal infections has also been investigated using mice deficient in the IFNAR1. During a lung <italic>Pneumocystis</italic> infection, a decreased pro-inflammatory response was detected and even if the pathogen burden was the same, the clearance was delayed in <italic>Ifnar1<sup>&#x02212;/&#x02212;</sup></italic> mice and this resulted in an exacerbated Th2 response and fibrosis (<xref rid="B111" ref-type="bibr">111</xref>). The lack of type I IFN signaling during <italic>Cryptococcus neoformans</italic> infection has been shown both to result in a decreased pathogen burden (<xref rid="B112" ref-type="bibr">112</xref>) and increased pathogen burden with increased death (<xref rid="B113" ref-type="bibr">113</xref>). However, both studies showed higher Th2 cytokine levels in the <italic>Ifnar1<sup>&#x02212;/&#x02212;</sup></italic> mice after <italic>C. neoformans</italic> infection (<xref rid="B112" ref-type="bibr">112</xref>, <xref rid="B113" ref-type="bibr">113</xref>). Thus, type I IFN responses during lung fungal infection are also part of driving the inflammatory response but it is still unclear in which magnitude or which mechanisms that are used.</p></sec></sec><sec id="S5"><title>Summary</title><p>There are obvious benefits of type I IFNs during a lung viral infection as these cytokines have a vital cell-intrinsic antiviral effect limiting viral replication. However, the cell-extrinsic effects of type I IFNs are important during all lung infections as type I IFNs directly drive lung inflammation, most likely by amplifying primary signals initiated by other stimuli. When considering to use type I IFN as a potential antiviral agent, the immune-modulating effects during lung infections needs to be considered as the type I IFN response has to be tightly regulated so that a balance of beneficial (initiation of inflammation) and detrimental (immunopathology) effects is achieved and gas exchange is not impaired.</p></sec><sec id="S6"><title>Author Contributions</title><p>CJ conceptualized the scope of the review article. CJ, SM, and MP wrote the review.</p></sec><sec id="S7"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><sec id="S8"><title>Funding</title><p>The authors want to thank the Medical Research Council (Grant G0800311), the Rosetrees Trust (M370), and the National Heart and Lung Institute Foundation (registered charity number 1048073) for research support. The authors also want to thank Caetano Reis e Sousa for critically reading the review.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopf</surname><given-names>M</given-names></name><name><surname>Schneider</surname><given-names>C</given-names></name><name><surname>Nobs</surname><given-names>SP</given-names></name></person-group>
<article-title>The development and function of lung-resident macrophages and dendritic cells</article-title>. <source>Nat Immunol</source> (<year>2014</year>) <volume>16</volume>:<fpage>36</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1038/ni.3052</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durbin</surname><given-names>RK</given-names></name><name><surname>Kotenko</surname><given-names>SV</given-names></name><name><surname>Durbin</surname><given-names>JE</given-names></name></person-group>. <article-title>Interferon induction and function at the mucosal surface</article-title>. <source>Immunol Rev</source> (<year>2013</year>) <volume>255</volume>:<fpage>25</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="doi">10.1111/imr.12101</pub-id><?supplied-pmid 23947345?><pub-id pub-id-type="pmid">23947345</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x000e1;lez-Navajas</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>David</surname><given-names>M</given-names></name><name><surname>Raz</surname><given-names>E</given-names></name></person-group>. <article-title>Immunomodulatory functions of type I interferons</article-title>. <source>Nat Rev Immunol</source> (<year>2012</year>) <volume>12</volume>:<fpage>125</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1038/nri3133</pub-id><?supplied-pmid 22222875?><pub-id pub-id-type="pmid">22222875</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swiecki</surname><given-names>M</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group>. <article-title>Type I interferons: diversity of sources, production pathways and effects on immune responses</article-title>. <source>Curr Opin Virol</source> (<year>2011</year>) <volume>1</volume>:<fpage>463</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1016/j.coviro.2011.10.026</pub-id><?supplied-pmid 22440910?><pub-id pub-id-type="pmid">22440910</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wack</surname><given-names>A</given-names></name><name><surname>Terczy&#x00144;ska-Dyla</surname><given-names>E</given-names></name><name><surname>Hartmann</surname><given-names>R</given-names></name></person-group>. <article-title>Guarding the frontiers: the biology of type III interferons</article-title>. <source>Nat Immunol</source> (<year>2015</year>) <volume>16</volume>:<fpage>802</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/ni.3212</pub-id><?supplied-pmid 26194286?><pub-id pub-id-type="pmid">26194286</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egli</surname><given-names>A</given-names></name><name><surname>Santer</surname><given-names>DM</given-names></name><name><surname>O&#x02019;Shea</surname><given-names>D</given-names></name><name><surname>Barakat</surname><given-names>K</given-names></name><name><surname>Syedbasha</surname><given-names>M</given-names></name><name><surname>Vollmer</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>IL-28B is a key regulator of B- and T-cell vaccine responses against influenza</article-title>. <source>PLoS Pathog</source> (<year>2014</year>) <volume>10</volume>:<fpage>e1004556</fpage>.<pub-id pub-id-type="doi">10.1371/journal.ppat.1004556</pub-id><?supplied-pmid 25503988?><pub-id pub-id-type="pmid">25503988</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prokunina-Olsson</surname><given-names>L</given-names></name><name><surname>Muchmore</surname><given-names>B</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Pfeiffer</surname><given-names>RM</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Dickensheets</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus</article-title>. <source>Nat Genet</source> (<year>2013</year>) <volume>45</volume>:<fpage>164</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1038/ng.2521</pub-id><?supplied-pmid 23291588?><pub-id pub-id-type="pmid">23291588</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNab</surname><given-names>F</given-names></name><name><surname>Mayer-Barber</surname><given-names>K</given-names></name><name><surname>Sher</surname><given-names>A</given-names></name><name><surname>Wack</surname><given-names>A</given-names></name><name><surname>O&#x02019;Garra</surname><given-names>A</given-names></name></person-group>. <article-title>Type I interferons in infectious disease</article-title>. <source>Nat Rev Immunol</source> (<year>2015</year>) <volume>15</volume>:<fpage>87</fpage>&#x02013;<lpage>103</lpage>.<pub-id pub-id-type="doi">10.1038/nri3787</pub-id><?supplied-pmid 25614319?><pub-id pub-id-type="pmid">25614319</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group>. <article-title>Toll-like receptors and their crosstalk with other innate receptors in infection and immunity</article-title>. <source>Immunity</source> (<year>2011</year>) <volume>34</volume>:<fpage>637</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2011.05.006</pub-id><?supplied-pmid 21616434?><pub-id pub-id-type="pmid">21616434</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loo</surname><given-names>Y-M</given-names></name><name><surname>Gale</surname><given-names>M</given-names></name></person-group>. <article-title>Immune signaling by RIG-I-like receptors</article-title>. <source>Immunity</source> (<year>2011</year>) <volume>34</volume>:<fpage>680</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2011.05.003</pub-id><?supplied-pmid 21616437?><pub-id pub-id-type="pmid">21616437</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goubau</surname><given-names>D</given-names></name><name><surname>Deddouche</surname><given-names>S</given-names></name><name><surname>Reis e Sousa</surname><given-names>C</given-names></name></person-group>. <article-title>Cytosolic sensing of viruses</article-title>. <source>Immunity</source> (<year>2013</year>) <volume>38</volume>:<fpage>855</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2013.05.007</pub-id><?supplied-pmid 23706667?><pub-id pub-id-type="pmid">23706667</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brubaker</surname><given-names>SW</given-names></name><name><surname>Bonham</surname><given-names>KS</given-names></name><name><surname>Zanoni</surname><given-names>I</given-names></name><name><surname>Kagan</surname><given-names>JC</given-names></name></person-group>. <article-title>Innate immune pattern recognition: a cell biological perspective</article-title>. <source>Annu Rev Immunol</source> (<year>2015</year>) <volume>33</volume>:<fpage>257</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1146/annurev-immunol-032414-112240</pub-id><?supplied-pmid 25581309?><pub-id pub-id-type="pmid">25581309</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000fc;rtler</surname><given-names>C</given-names></name><name><surname>Bowie</surname><given-names>AG</given-names></name></person-group>. <article-title>Innate immune detection of microbial nucleic acids</article-title>. <source>Trends Microbiol</source> (<year>2013</year>) <volume>21</volume>:<fpage>413</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1016/j.tim.2013.04.004</pub-id><?supplied-pmid 23726320?><pub-id pub-id-type="pmid">23726320</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Neill</surname><given-names>LAJ</given-names></name><name><surname>Golenbock</surname><given-names>D</given-names></name><name><surname>Bowie</surname><given-names>AG</given-names></name></person-group>. <article-title>The history of toll-like receptors &#x02013; redefining innate immunity</article-title>. <source>Nat Rev Immunol</source> (<year>2013</year>) <volume>13</volume>:<fpage>453</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1038/nri3446</pub-id><?supplied-pmid 23681101?><pub-id pub-id-type="pmid">23681101</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>KA</given-names></name><name><surname>Rowe</surname><given-names>DC</given-names></name><name><surname>Barnes</surname><given-names>BJ</given-names></name><name><surname>Caffrey</surname><given-names>DR</given-names></name><name><surname>Visintin</surname><given-names>A</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF</article-title>. <source>J Exp Med</source> (<year>2003</year>) <volume>198</volume>:<fpage>1043</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20031023</pub-id><?supplied-pmid 14517278?><pub-id pub-id-type="pmid">14517278</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurt-Jones</surname><given-names>EA</given-names></name><name><surname>Popova</surname><given-names>L</given-names></name><name><surname>Kwinn</surname><given-names>L</given-names></name><name><surname>Haynes</surname><given-names>LM</given-names></name><name><surname>Jones</surname><given-names>LP</given-names></name><name><surname>Tripp</surname><given-names>RA</given-names></name><etal/></person-group>
<article-title>Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus</article-title>. <source>Nat Immunol</source> (<year>2000</year>) <volume>1</volume>:<fpage>398</fpage>&#x02013;<lpage>401</lpage>.<pub-id pub-id-type="doi">10.1038/80833</pub-id><?supplied-pmid 11062499?><pub-id pub-id-type="pmid">11062499</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goubau</surname><given-names>D</given-names></name><name><surname>Schlee</surname><given-names>M</given-names></name><name><surname>Deddouche</surname><given-names>S</given-names></name><name><surname>Pruijssers</surname><given-names>AJ</given-names></name><name><surname>Zillinger</surname><given-names>T</given-names></name><name><surname>Goldeck</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5&#x02019;-diphosphates</article-title>. <source>Nature</source> (<year>2014</year>) <volume>514</volume>:<fpage>372</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1038/nature13590</pub-id><?supplied-pmid 25119032?><pub-id pub-id-type="pmid">25119032</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hornung</surname><given-names>V</given-names></name><name><surname>Ellegast</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Brz&#x000f3;zka</surname><given-names>K</given-names></name><name><surname>Jung</surname><given-names>A</given-names></name><name><surname>Kato</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>5&#x02019;-Triphosphate RNA is the ligand for RIG-I</article-title>. <source>Science</source> (<year>2006</year>) <volume>314</volume>:<fpage>994</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1126/science.1132505</pub-id><?supplied-pmid 17038590?><pub-id pub-id-type="pmid">17038590</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pichlmair</surname><given-names>A</given-names></name><name><surname>Schulz</surname><given-names>O</given-names></name><name><surname>Tan</surname><given-names>CP</given-names></name><name><surname>N&#x000e4;slund</surname><given-names>TI</given-names></name><name><surname>Liljestr&#x000f6;m</surname><given-names>P</given-names></name><name><surname>Weber</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>RIG-I-mediated antiviral responses to single-stranded RNA bearing 5&#x02019;-phosphates</article-title>. <source>Science</source> (<year>2006</year>) <volume>314</volume>:<fpage>997</fpage>&#x02013;<lpage>1001</lpage>.<pub-id pub-id-type="doi">10.1126/science.1132998</pub-id><?supplied-pmid 17038589?><pub-id pub-id-type="pmid">17038589</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruns</surname><given-names>AM</given-names></name><name><surname>Leser</surname><given-names>GP</given-names></name><name><surname>Lamb</surname><given-names>RA</given-names></name><name><surname>Horvath</surname><given-names>CM</given-names></name></person-group>. <article-title>The innate immune sensor LGP2 activates antiviral signaling by regulating MDA5-RNA interaction and filament assembly</article-title>. <source>Mol Cell</source> (<year>2014</year>) <volume>55</volume>:<fpage>771</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1016/j.molcel.2014.07.003</pub-id><?supplied-pmid 25127512?><pub-id pub-id-type="pmid">25127512</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Cong</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation</article-title>. <source>Science</source> (<year>2015</year>) <volume>347</volume>(<issue>6227</issue>):<fpage>aaa2630</fpage>.<pub-id pub-id-type="doi">10.1126/science.aaa2630</pub-id><?supplied-pmid 25636800?><pub-id pub-id-type="pmid">25636800</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Hur</surname><given-names>S</given-names></name></person-group>. <article-title>How RIG-I like receptors activate MAVS</article-title>. <source>Curr Opin Virol</source> (<year>2015</year>) <volume>12</volume>:<fpage>91</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.coviro.2015.04.004</pub-id><?supplied-pmid 25942693?><pub-id pub-id-type="pmid">25942693</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>KJ</given-names></name><name><surname>Kawagoe</surname><given-names>T</given-names></name><name><surname>Koyama</surname><given-names>S</given-names></name><name><surname>Matsui</surname><given-names>K</given-names></name><name><surname>Kumar</surname><given-names>H</given-names></name><name><surname>Kawai</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines</article-title>. <source>Nature</source> (<year>2008</year>) <volume>451</volume>:<fpage>725</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/nature06537</pub-id><?supplied-pmid 18256672?><pub-id pub-id-type="pmid">18256672</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paludan</surname><given-names>SR</given-names></name><name><surname>Bowie</surname><given-names>AG</given-names></name></person-group>
<article-title>Immune sensing of DNA</article-title>. <source>Immunity</source> (<year>2013</year>) <volume>38</volume>:<fpage>870</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2013.05.004</pub-id><pub-id pub-id-type="pmid">23706668</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>Y-H</given-names></name><name><surname>Macmillan</surname><given-names>JB</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group>. <article-title>RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway</article-title>. <source>Cell</source> (<year>2009</year>) <volume>138</volume>:<fpage>576</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2009.06.015</pub-id><?supplied-pmid 19631370?><pub-id pub-id-type="pmid">19631370</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schattgen</surname><given-names>SA</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Kurt-Jones</surname><given-names>EA</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name></person-group>. <article-title>Cutting edge: DNA in the lung microenvironment during influenza virus infection tempers inflammation by engaging the DNA sensor AIM2</article-title>. <source>J Immunol</source> (<year>2016</year>) <volume>196</volume>:<fpage>29</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1501048</pub-id><?supplied-pmid 26590313?><pub-id pub-id-type="pmid">26590313</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group>. <article-title>STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway</article-title>. <source>Sci Signal</source> (<year>2012</year>) <volume>5</volume>:<fpage>ra20</fpage>.<pub-id pub-id-type="doi">10.1126/scisignal.2002521</pub-id><?supplied-pmid 22394562?><pub-id pub-id-type="pmid">22394562</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group>. <article-title>Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway</article-title>. <source>Science</source> (<year>2013</year>) <volume>339</volume>:<fpage>786</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1126/science.1232458</pub-id><?supplied-pmid 23258413?><pub-id pub-id-type="pmid">23258413</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ablasser</surname><given-names>A</given-names></name><name><surname>Goldeck</surname><given-names>M</given-names></name><name><surname>Cavlar</surname><given-names>T</given-names></name><name><surname>Deimling</surname><given-names>T</given-names></name><name><surname>Witte</surname><given-names>G</given-names></name><name><surname>R&#x000f6;hl</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>cGAS produces a 2&#x02019;-5&#x02019;-linked cyclic dinucleotide second messenger that activates STING</article-title>. <source>Nature</source> (<year>2013</year>) <volume>498</volume>:<fpage>380</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1038/nature12306</pub-id><pub-id pub-id-type="pmid">23722158</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>F</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA</article-title>. <source>Science</source> (<year>2013</year>) <volume>339</volume>:<fpage>826</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1126/science.1229963</pub-id><pub-id pub-id-type="pmid">23258412</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ablasser</surname><given-names>A</given-names></name><name><surname>Schmid-Burgk</surname><given-names>JL</given-names></name><name><surname>Hemmerling</surname><given-names>I</given-names></name><name><surname>Horvath</surname><given-names>GL</given-names></name><name><surname>Schmidt</surname><given-names>T</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP</article-title>. <source>Nature</source> (<year>2013</year>) <volume>503</volume>:<fpage>530</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1038/nature12640</pub-id><?supplied-pmid 24077100?><pub-id pub-id-type="pmid">24077100</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crotta</surname><given-names>S</given-names></name><name><surname>Davidson</surname><given-names>S</given-names></name><name><surname>Mahlakoiv</surname><given-names>T</given-names></name><name><surname>Desmet</surname><given-names>CJ</given-names></name><name><surname>Buckwalter</surname><given-names>MR</given-names></name><name><surname>Albert</surname><given-names>ML</given-names></name><etal/></person-group>
<article-title>Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia</article-title>. <source>PLoS Pathog</source> (<year>2013</year>) <volume>9</volume>:<fpage>e1003773</fpage>.<pub-id pub-id-type="doi">10.1371/journal.ppat.1003773</pub-id><?supplied-pmid 24278020?><pub-id pub-id-type="pmid">24278020</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group>. <article-title>The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors</article-title>. <source>Nat Immunol</source> (<year>2010</year>) <volume>11</volume>:<fpage>373</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1038/ni.1863</pub-id><?supplied-pmid 20404851?><pub-id pub-id-type="pmid">20404851</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwasaki</surname><given-names>A</given-names></name><name><surname>Pillai</surname><given-names>PS</given-names></name></person-group>. <article-title>Innate immunity to influenza virus infection</article-title>. <source>Nat Rev Immunol</source> (<year>2014</year>) <volume>14</volume>:<fpage>315</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="doi">10.1038/nri3665</pub-id><?supplied-pmid 24762827?><pub-id pub-id-type="pmid">24762827</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goritzka</surname><given-names>M</given-names></name><name><surname>Makris</surname><given-names>S</given-names></name><name><surname>Kausar</surname><given-names>F</given-names></name><name><surname>Durant</surname><given-names>LR</given-names></name><name><surname>Pereira</surname><given-names>C</given-names></name><name><surname>Kumagai</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Alveolar macrophage-derived type I interferons orchestrate innate immunity to RSV through recruitment of antiviral monocytes</article-title>. <source>J Exp Med</source> (<year>2015</year>) <volume>212</volume>:<fpage>699</fpage>&#x02013;<lpage>714</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20140825</pub-id><?supplied-pmid 25897172?><pub-id pub-id-type="pmid">25897172</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platanias</surname><given-names>LC</given-names></name></person-group>. <article-title>Mechanisms of type-I- and type-II-interferon-mediated signalling</article-title>. <source>Nat Rev Immunol</source> (<year>2005</year>) <volume>5</volume>:<fpage>375</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1038/nri1604</pub-id><?supplied-pmid 15864272?><pub-id pub-id-type="pmid">15864272</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoggins</surname><given-names>JW</given-names></name><name><surname>Wilson</surname><given-names>SJ</given-names></name><name><surname>Panis</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>MY</given-names></name><name><surname>Jones</surname><given-names>CT</given-names></name><name><surname>Bieniasz</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>A diverse range of gene products are effectors of the type I interferon antiviral response</article-title>. <source>Nature</source> (<year>2011</year>) <volume>472</volume>:<fpage>481</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1038/nature09907</pub-id><pub-id pub-id-type="pmid">21478870</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoggins</surname><given-names>JW</given-names></name></person-group>. <article-title>Interferon-stimulated genes: roles in viral pathogenesis</article-title>. <source>Curr Opin Virol</source> (<year>2014</year>) <volume>6</volume>:<fpage>40</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.coviro.2014.03.006</pub-id><?supplied-pmid 24713352?><pub-id pub-id-type="pmid">24713352</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stark</surname><given-names>GR</given-names></name><name><surname>Darnell</surname><given-names>JE</given-names></name></person-group>. <article-title>The JAK-STAT pathway at twenty</article-title>. <source>Immunity</source> (<year>2012</year>) <volume>36</volume>:<fpage>503</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2012.03.013</pub-id><?supplied-pmid 22520844?><pub-id pub-id-type="pmid">22520844</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>WM</given-names></name><name><surname>Chevillotte</surname><given-names>MD</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name></person-group>. <article-title>Interferon-stimulated genes: a complex web of host defenses</article-title>. <source>Annu Rev Immunol</source> (<year>2014</year>) <volume>32</volume>:<fpage>513</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120231</pub-id><?supplied-pmid 24555472?><pub-id pub-id-type="pmid">24555472</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>C</given-names></name><name><surname>Moraga</surname><given-names>I</given-names></name><name><surname>Levin</surname><given-names>D</given-names></name><name><surname>Krutzik</surname><given-names>PO</given-names></name><name><surname>Podoplelova</surname><given-names>Y</given-names></name><name><surname>Trejo</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Structural linkage between ligand discrimination and receptor activation by type I interferons</article-title>. <source>Cell</source> (<year>2011</year>) <volume>146</volume>:<fpage>621</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2011.06.048</pub-id><?supplied-pmid 21854986?><pub-id pub-id-type="pmid">21854986</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Weerd</surname><given-names>NA</given-names></name><name><surname>Vivian</surname><given-names>JP</given-names></name><name><surname>Nguyen</surname><given-names>TK</given-names></name><name><surname>Mangan</surname><given-names>NE</given-names></name><name><surname>Gould</surname><given-names>JA</given-names></name><name><surname>Braniff</surname><given-names>S-J</given-names></name><etal/></person-group>
<article-title>Structural basis of a unique interferon-&#x003b2; signaling axis mediated via the receptor IFNAR1</article-title>. <source>Nat Immunol</source> (<year>2013</year>) <volume>14</volume>:<fpage>901</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1038/ni.2667</pub-id><?supplied-pmid 23872679?><pub-id pub-id-type="pmid">23872679</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>K</given-names></name><name><surname>Yanai</surname><given-names>H</given-names></name><name><surname>Negishi</surname><given-names>H</given-names></name><name><surname>Asagiri</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Mizutani</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>IRF-7 is the master regulator of type-I interferon-dependent immune responses</article-title>. <source>Nature</source> (<year>2005</year>) <volume>434</volume>:<fpage>772</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1038/nature03464</pub-id><?supplied-pmid 15800576?><pub-id pub-id-type="pmid">15800576</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mari&#x000e9;</surname><given-names>I</given-names></name><name><surname>Durbin</surname><given-names>JE</given-names></name><name><surname>Levy</surname><given-names>DE</given-names></name></person-group>
<article-title>Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7</article-title>. <source>EMBO J</source> (<year>1998</year>) <volume>17</volume>:<fpage>6660</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1093/emboj/17.22.6660</pub-id><pub-id pub-id-type="pmid">9822609</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivashkiv</surname><given-names>LB</given-names></name><name><surname>Donlin</surname><given-names>LT</given-names></name></person-group>
<article-title>Regulation of type I interferon responses</article-title>. <source>Nat Rev Immunol</source> (<year>2013</year>) <volume>14</volume>:<fpage>36</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="doi">10.1038/nri3581</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sancho-Shimizu</surname><given-names>V</given-names></name><name><surname>P&#x000e9;rez de Diego</surname><given-names>R</given-names></name><name><surname>Jouanguy</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>S-Y</given-names></name><name><surname>Casanova</surname><given-names>J-L</given-names></name></person-group>. <article-title>Inborn errors of anti-viral interferon immunity in humans</article-title>. <source>Curr Opin Virol</source> (<year>2011</year>) <volume>1</volume>:<fpage>487</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.1016/j.coviro.2011.10.016</pub-id><?supplied-pmid 22347990?><pub-id pub-id-type="pmid">22347990</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S-Y</given-names></name><name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name><name><surname>Chapgier</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Bustamante</surname><given-names>J</given-names></name><name><surname>Puel</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense</article-title>. <source>Immunol Rev</source> (<year>2008</year>) <volume>226</volume>:<fpage>29</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1111/j.1600-065X.2008.00698.x</pub-id><?supplied-pmid 19161414?><pub-id pub-id-type="pmid">19161414</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciancanelli</surname><given-names>MJ</given-names></name><name><surname>Huang</surname><given-names>SXL</given-names></name><name><surname>Luthra</surname><given-names>P</given-names></name><name><surname>Garner</surname><given-names>H</given-names></name><name><surname>Itan</surname><given-names>Y</given-names></name><name><surname>Volpi</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency</article-title>. <source>Science</source> (<year>2015</year>) <volume>348</volume>:<fpage>448</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1126/science.aaa1578</pub-id><?supplied-pmid 25814066?><pub-id pub-id-type="pmid">25814066</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>R</given-names></name><name><surname>Bont</surname><given-names>L</given-names></name><name><surname>Siezen</surname><given-names>CLE</given-names></name><name><surname>Hodemaekers</surname><given-names>HM</given-names></name><name><surname>Ermers</surname><given-names>MJ</given-names></name><name><surname>Doornbos</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes</article-title>. <source>J Infect Dis</source> (<year>2007</year>) <volume>196</volume>:<fpage>826</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1086/520886</pub-id><?supplied-pmid 17703412?><pub-id pub-id-type="pmid">17703412</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siezen</surname><given-names>CLE</given-names></name><name><surname>Bont</surname><given-names>L</given-names></name><name><surname>Hodemaekers</surname><given-names>HM</given-names></name><name><surname>Ermers</surname><given-names>MJ</given-names></name><name><surname>Doornbos</surname><given-names>G</given-names></name><name><surname>Van&#x02019;t Slot</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Genetic susceptibility to respiratory syncytial virus bronchiolitis in preterm children is associated with airway remodeling genes and innate immune genes</article-title>. <source>Pediatr Infect Dis J</source> (<year>2009</year>) <volume>28</volume>:<fpage>333</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1097/INF.0b013e31818e2aa9</pub-id><?supplied-pmid 19258923?><pub-id pub-id-type="pmid">19258923</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everitt</surname><given-names>AR</given-names></name><name><surname>Clare</surname><given-names>S</given-names></name><name><surname>Pertel</surname><given-names>T</given-names></name><name><surname>John</surname><given-names>SP</given-names></name><name><surname>Wash</surname><given-names>RS</given-names></name><name><surname>Smith</surname><given-names>SE</given-names></name><etal/></person-group>
<article-title>IFITM3 restricts the morbidity and mortality associated with influenza</article-title>. <source>Nature</source> (<year>2012</year>) <volume>484</volume>:<fpage>519</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1038/nature10921</pub-id><?supplied-pmid 22446628?><pub-id pub-id-type="pmid">22446628</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y-H</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Peng</surname><given-names>Y-C</given-names></name><name><surname>Giannoulatou</surname><given-names>E</given-names></name><name><surname>Jin</surname><given-names>R-H</given-names></name><etal/></person-group>
<article-title>Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals</article-title>. <source>Nat Commun</source> (<year>2013</year>) <volume>4</volume>:<fpage>1418</fpage>.<pub-id pub-id-type="doi">10.1038/ncomms2433</pub-id><?supplied-pmid 23361009?><pub-id pub-id-type="pmid">23361009</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillai</surname><given-names>PS</given-names></name><name><surname>Molony</surname><given-names>RD</given-names></name><name><surname>Martinod</surname><given-names>K</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Pang</surname><given-names>IK</given-names></name><name><surname>Tal</surname><given-names>MC</given-names></name><etal/></person-group>
<article-title>Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease</article-title>. <source>Science</source> (<year>2016</year>) <volume>352</volume>:<fpage>463</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1126/science.aaf3926</pub-id><?supplied-pmid 27102485?><pub-id pub-id-type="pmid">27102485</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciancanelli</surname><given-names>MJ</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>S-Y</given-names></name><name><surname>Casanova</surname><given-names>J-L</given-names></name></person-group>. <article-title>Host genetics of severe influenza: from mouse Mx1 to human IRF7</article-title>. <source>Curr Opin Immunol</source> (<year>2016</year>) <volume>38</volume>:<fpage>109</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1016/j.coi.2015.12.002</pub-id><?supplied-pmid 26761402?><pub-id pub-id-type="pmid">26761402</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trinchieri</surname><given-names>G</given-names></name></person-group>. <article-title>Type I interferon: friend or foe?</article-title>
<source>J Exp Med</source> (<year>2010</year>) <volume>207</volume>:<fpage>2053</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20101664</pub-id><?supplied-pmid 20837696?><pub-id pub-id-type="pmid">20837696</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goritzka</surname><given-names>M</given-names></name><name><surname>Durant</surname><given-names>LR</given-names></name><name><surname>Pereira</surname><given-names>C</given-names></name><name><surname>Salek-Ardakani</surname><given-names>S</given-names></name><name><surname>Openshaw</surname><given-names>PJM</given-names></name><name><surname>Johansson</surname><given-names>C</given-names></name></person-group>
<article-title>Interferon-&#x003b1;/&#x003b2; receptor signaling amplifies early pro-inflammatory cytokine production in the lung during respiratory syncytial virus infection</article-title>. <source>J Virol</source> (<year>2014</year>) <volume>88</volume>:<fpage>6128</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="doi">10.1128/JVI.00333-14</pub-id><pub-id pub-id-type="pmid">24648449</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>MH</given-names></name><name><surname>Torres-Dom&#x000ed;nguez</surname><given-names>LE</given-names></name><name><surname>Price</surname><given-names>PJR</given-names></name><name><surname>Brandm&#x000fc;ller</surname><given-names>C</given-names></name><name><surname>Kirschning</surname><given-names>CJ</given-names></name><name><surname>Sutter</surname><given-names>G</given-names></name></person-group>. <article-title>CCL2 expression is mediated by type I IFN receptor and recruits NK and T cells to the lung during MVA infection</article-title>. <source>J Leukoc Biol</source> (<year>2016</year>) <volume>99</volume>:<fpage>1057</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="doi">10.1189/jlb.4MA0815-376RR</pub-id><?supplied-pmid 26992431?><pub-id pub-id-type="pmid">26992431</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stetson</surname><given-names>DB</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group>. <article-title>Type I interferons in host defense</article-title>. <source>Immunity</source> (<year>2006</year>) <volume>25</volume>:<fpage>373</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2006.08.007</pub-id><?supplied-pmid 16979569?><pub-id pub-id-type="pmid">16979569</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Amakawa</surname><given-names>R</given-names></name><name><surname>Inaba</surname><given-names>M</given-names></name><name><surname>Ikehara</surname><given-names>S</given-names></name><name><surname>Inaba</surname><given-names>K</given-names></name><name><surname>Fukuhara</surname><given-names>S</given-names></name></person-group>
<article-title>Differential regulation of human blood dendritic cell subsets by IFNs</article-title>. <source>J Immunol</source> (<year>2001</year>) <volume>166</volume>:<fpage>2961</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.166.5.2961</pub-id><pub-id pub-id-type="pmid">11207245</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Bon</surname><given-names>A</given-names></name><name><surname>Etchart</surname><given-names>N</given-names></name><name><surname>Rossmann</surname><given-names>C</given-names></name><name><surname>Ashton</surname><given-names>M</given-names></name><name><surname>Hou</surname><given-names>S</given-names></name><name><surname>Gewert</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon</article-title>. <source>Nat Immunol</source> (<year>2003</year>) <volume>4</volume>:<fpage>1009</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1038/ni978</pub-id><?supplied-pmid 14502286?><pub-id pub-id-type="pmid">14502286</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouzaut</surname><given-names>A</given-names></name><name><surname>Garasa</surname><given-names>S</given-names></name><name><surname>Teijeira</surname><given-names>A</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>I</given-names></name><name><surname>Martinez-Forero</surname><given-names>I</given-names></name><name><surname>Suarez</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-&#x003b1;</article-title>. <source>Eur J Immunol</source> (<year>2010</year>) <volume>40</volume>:<fpage>3054</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201040523</pub-id><?supplied-pmid 21061437?><pub-id pub-id-type="pmid">21061437</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spadaro</surname><given-names>F</given-names></name><name><surname>Lapenta</surname><given-names>C</given-names></name><name><surname>Donati</surname><given-names>S</given-names></name><name><surname>Abalsamo</surname><given-names>L</given-names></name><name><surname>Barnaba</surname><given-names>V</given-names></name><name><surname>Belardelli</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>IFN-&#x003b1; enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing</article-title>. <source>Blood</source> (<year>2012</year>) <volume>119</volume>:<fpage>1407</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2011-06-363564</pub-id><?supplied-pmid 22184405?><pub-id pub-id-type="pmid">22184405</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crouse</surname><given-names>J</given-names></name><name><surname>Kalinke</surname><given-names>U</given-names></name><name><surname>Oxenius</surname><given-names>A</given-names></name></person-group>. <article-title>Regulation of antiviral T cell responses by type I interferons</article-title>. <source>Nat Rev Immunol</source> (<year>2015</year>) <volume>15</volume>:<fpage>231</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1038/nri3806</pub-id><?supplied-pmid 25790790?><pub-id pub-id-type="pmid">25790790</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asselin-Paturel</surname><given-names>C</given-names></name><name><surname>Brizard</surname><given-names>G</given-names></name><name><surname>Chemin</surname><given-names>K</given-names></name><name><surname>Boonstra</surname><given-names>A</given-names></name><name><surname>O&#x02019;Garra</surname><given-names>A</given-names></name><name><surname>Vicari</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Type I interferon dependence of plasmacytoid dendritic cell activation and migration</article-title>. <source>J Exp Med</source> (<year>2005</year>) <volume>201</volume>:<fpage>1157</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20041930</pub-id><?supplied-pmid 15795237?><pub-id pub-id-type="pmid">15795237</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longhi</surname><given-names>MP</given-names></name><name><surname>Trumpfheller</surname><given-names>C</given-names></name><name><surname>Idoyaga</surname><given-names>J</given-names></name><name><surname>Caskey</surname><given-names>M</given-names></name><name><surname>Matos</surname><given-names>I</given-names></name><name><surname>Kluger</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant</article-title>. <source>J Exp Med</source> (<year>2009</year>) <volume>206</volume>:<fpage>1589</fpage>&#x02013;<lpage>602</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20090247</pub-id><?supplied-pmid 19564349?><pub-id pub-id-type="pmid">19564349</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>K</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name><name><surname>Nakajima</surname><given-names>C</given-names></name><name><surname>Watanabe</surname><given-names>A</given-names></name><name><surname>Yanai</surname><given-names>H</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2003</year>) <volume>100</volume>:<fpage>10872</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1934678100</pub-id><?supplied-pmid 12960379?><pub-id pub-id-type="pmid">12960379</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moltedo</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Yount</surname><given-names>JS</given-names></name><name><surname>Moran</surname><given-names>TM</given-names></name></person-group>. <article-title>Unique type I interferon responses determine the functional fate of migratory lung dendritic cells during influenza virus infection</article-title>. <source>PLoS Pathog</source> (<year>2011</year>) <volume>7</volume>:<fpage>e1002345</fpage>.<pub-id pub-id-type="doi">10.1371/journal.ppat.1002345</pub-id><?supplied-pmid 22072965?><pub-id pub-id-type="pmid">22072965</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hervas-Stubbs</surname><given-names>S</given-names></name><name><surname>Perez-Gracia</surname><given-names>JL</given-names></name><name><surname>Rouzaut</surname><given-names>A</given-names></name><name><surname>Sanmamed</surname><given-names>MF</given-names></name><name><surname>Le Bon</surname><given-names>A</given-names></name><name><surname>Melero</surname><given-names>I</given-names></name></person-group>
<article-title>Direct effects of type I interferons on cells of the immune system</article-title>. <source>Clin Cancer Res</source> (<year>2011</year>) <volume>17</volume>:<fpage>2619</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-1114</pub-id><pub-id pub-id-type="pmid">21372217</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tough</surname><given-names>DF</given-names></name></person-group>
<article-title>Modulation of T-cell function by type I interferon</article-title>. <source>Immunol Cell Biol</source> (<year>2012</year>) <volume>90</volume>:<fpage>492</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1038/icb.2012.7</pub-id><pub-id pub-id-type="pmid">22391814</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Bon</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>C</given-names></name><name><surname>Kamphuis</surname><given-names>E</given-names></name><name><surname>Durand</surname><given-names>V</given-names></name><name><surname>Rossmann</surname><given-names>C</given-names></name><name><surname>Kalinke</surname><given-names>U</given-names></name><etal/></person-group>
<article-title>Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN</article-title>. <source>J Immunol</source> (<year>2006</year>) <volume>176</volume>:<fpage>2074</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.176.4.2074</pub-id><?supplied-pmid 16455962?><pub-id pub-id-type="pmid">16455962</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>WLW</given-names></name><name><surname>Coro</surname><given-names>ES</given-names></name><name><surname>Rau</surname><given-names>FC</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Erle</surname><given-names>DJ</given-names></name><name><surname>Baumgarth</surname><given-names>N</given-names></name></person-group>. <article-title>Influenza virus infection causes global respiratory tract B cell response modulation via innate immune signals</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>178</volume>:<fpage>1457</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.178.3.1457</pub-id><?supplied-pmid 17237394?><pub-id pub-id-type="pmid">17237394</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moseman</surname><given-names>EA</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>la Torre de</surname><given-names>JC</given-names></name><name><surname>Schwartzberg</surname><given-names>PL</given-names></name><name><surname>McGavern</surname><given-names>DB</given-names></name></person-group>
<article-title>Type I interferon suppresses virus-specific B cell responses by modulating CD8<sup>+</sup> T cell differentiation</article-title>. <source>Sci Immunol</source> (<year>2016</year>) <volume>1</volume>(<issue>4</issue>).<pub-id pub-id-type="doi">10.1126/sciimmunol.aah3565</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>S</given-names></name><name><surname>McCabe</surname><given-names>TM</given-names></name><name><surname>Crotta</surname><given-names>S</given-names></name><name><surname>Gad</surname><given-names>HH</given-names></name><name><surname>Hessel</surname><given-names>EM</given-names></name><name><surname>Beinke</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>IFN&#x003bb; is a potent anti-influenza therapeutic without the inflammatory side effects of IFN&#x003b1; treatment</article-title>. <source>EMBO Mol Med</source> (<year>2016</year>) <volume>8</volume>:<fpage>1099</fpage>&#x02013;<lpage>112</lpage>.<pub-id pub-id-type="doi">10.15252/emmm.201606413</pub-id><?supplied-pmid 27520969?><pub-id pub-id-type="pmid">27520969</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeffer</surname><given-names>LM</given-names></name></person-group>. <article-title>The role of nuclear factor &#x003ba;B in the interferon response</article-title>. <source>J Interferon Cytokine Res</source> (<year>2011</year>) <volume>31</volume>:<fpage>553</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1089/jir.2011.0028</pub-id><?supplied-pmid 21631354?><pub-id pub-id-type="pmid">21631354</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattei</surname><given-names>F</given-names></name><name><surname>Schiavoni</surname><given-names>G</given-names></name><name><surname>Tough</surname><given-names>DF</given-names></name></person-group>. <article-title>Regulation of immune cell homeostasis by type I interferons</article-title>. <source>Cytokine Growth Factor Rev</source> (<year>2010</year>) <volume>21</volume>:<fpage>227</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="doi">10.1016/j.cytogfr.2010.05.002</pub-id><?supplied-pmid 20627800?><pub-id pub-id-type="pmid">20627800</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haller</surname><given-names>O</given-names></name><name><surname>Kochs</surname><given-names>G</given-names></name><name><surname>Weber</surname><given-names>F</given-names></name></person-group>. <article-title>The interferon response circuit: induction and suppression by pathogenic viruses</article-title>. <source>Virology</source> (<year>2006</year>) <volume>344</volume>:<fpage>119</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1016/j.virol.2005.09.024</pub-id><?supplied-pmid 16364743?><pub-id pub-id-type="pmid">16364743</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaitin</surname><given-names>DA</given-names></name><name><surname>Schreiber</surname><given-names>G</given-names></name></person-group>. <article-title>Upregulation of a small subset of genes drives type I interferon-induced antiviral memory</article-title>. <source>J Interferon Cytokine Res</source> (<year>2007</year>) <volume>27</volume>:<fpage>653</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="doi">10.1089/jir.2006.0162</pub-id><?supplied-pmid 17784817?><pub-id pub-id-type="pmid">17784817</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R</given-names></name><name><surname>Fehr</surname><given-names>AR</given-names></name><name><surname>Vijay</surname><given-names>R</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Meyerholz</surname><given-names>DK</given-names></name><etal/></person-group>
<article-title>Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice</article-title>. <source>Cell Host Microbe</source> (<year>2016</year>) <volume>19</volume>:<fpage>181</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="doi">10.1016/j.chom.2016.01.007</pub-id><?supplied-pmid 26867177?><pub-id pub-id-type="pmid">26867177</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>BX</given-names></name><name><surname>Fish</surname><given-names>EN</given-names></name></person-group>. <article-title>The yin and yang of viruses and interferons</article-title>. <source>Trends Immunol</source> (<year>2012</year>) <volume>33</volume>:<fpage>190</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.it.2012.01.004</pub-id><?supplied-pmid 22321608?><pub-id pub-id-type="pmid">22321608</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KS</given-names></name><name><surname>Mossman</surname><given-names>KL</given-names></name></person-group>
<article-title>Viral evasion strategies in type I IFN signaling &#x02013; a summary of recent developments</article-title>. <source>Front Immunol</source> (<year>2016</year>) <volume>7</volume>:<fpage>459</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2016.00498</pub-id><pub-id pub-id-type="pmid">27833612</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coccia</surname><given-names>EM</given-names></name><name><surname>Battistini</surname><given-names>A</given-names></name></person-group>. <article-title>Early IFN type I response: learning from microbial evasion strategies</article-title>. <source>Semin Immunol</source> (<year>2015</year>) <volume>27</volume>:<fpage>85</fpage>&#x02013;<lpage>101</lpage>.<pub-id pub-id-type="doi">10.1016/j.smim.2015.03.005</pub-id><?supplied-pmid 25869307?><pub-id pub-id-type="pmid">25869307</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jewell</surname><given-names>NA</given-names></name><name><surname>Vaghefi</surname><given-names>N</given-names></name><name><surname>Mertz</surname><given-names>SE</given-names></name><name><surname>Akter</surname><given-names>P</given-names></name><name><surname>Peebles</surname><given-names>RS</given-names></name><name><surname>Bakaletz</surname><given-names>LO</given-names></name><etal/></person-group>
<article-title>Differential type I interferon induction by respiratory syncytial virus and influenza a virus in vivo</article-title>. <source>J Virol</source> (<year>2007</year>) <volume>81</volume>:<fpage>9790</fpage>&#x02013;<lpage>800</lpage>.<pub-id pub-id-type="doi">10.1128/JVI.00530-07</pub-id><?supplied-pmid 17626092?><pub-id pub-id-type="pmid">17626092</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>S</given-names></name><name><surname>Crotta</surname><given-names>S</given-names></name><name><surname>McCabe</surname><given-names>TM</given-names></name><name><surname>Wack</surname><given-names>A</given-names></name></person-group>
<article-title>Pathogenic potential of interferon &#x003b1;&#x003b2; in acute influenza infection</article-title>. <source>Nat Commun</source> (<year>2014</year>) <volume>5</volume>:<fpage>3864</fpage><pub-id pub-id-type="doi">10.1038/ncomms4864</pub-id><pub-id pub-id-type="pmid">24844667</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cormier</surname><given-names>SA</given-names></name><name><surname>Shrestha</surname><given-names>B</given-names></name><name><surname>Saravia</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>GI</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>DeVincenzo</surname><given-names>JP</given-names></name><etal/></person-group>
<article-title>Limited type I interferons and plasmacytoid dendritic cells during neonatal respiratory syncytial virus infection permit immunopathogenesis upon reinfection</article-title>. <source>J Virol</source> (<year>2014</year>) <volume>88</volume>:<fpage>9350</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1128/JVI.00818-14</pub-id><?supplied-pmid 24920801?><pub-id pub-id-type="pmid">24920801</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remot</surname><given-names>A</given-names></name><name><surname>Descamps</surname><given-names>D</given-names></name><name><surname>Jouneau</surname><given-names>L</given-names></name><name><surname>Laubreton</surname><given-names>D</given-names></name><name><surname>Dubuquoy</surname><given-names>C</given-names></name><name><surname>Bouet</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Flt3 ligand improves the innate response to respiratory syncytial virus and limits lung disease upon RSV re-exposure in neonate mice</article-title>. <source>Eur J Immunol</source> (<year>2015</year>) <volume>46</volume>:<fpage>874</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201545929</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marr</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>TI</given-names></name><name><surname>Kam</surname><given-names>SHY</given-names></name><name><surname>Hu</surname><given-names>YS</given-names></name><name><surname>Sharma</surname><given-names>AA</given-names></name><name><surname>Lam</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Attenuation of respiratory syncytial virus-induced and RIG-I-dependent type I IFN responses in human neonates and very young children</article-title>. <source>J Immunol</source> (<year>2014</year>) <volume>192</volume>:<fpage>948</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1302007</pub-id><?supplied-pmid 24391215?><pub-id pub-id-type="pmid">24391215</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hastings</surname><given-names>AK</given-names></name><name><surname>Erickson</surname><given-names>JJ</given-names></name><name><surname>Schuster</surname><given-names>JE</given-names></name><name><surname>Boyd</surname><given-names>KL</given-names></name><name><surname>Tollefson</surname><given-names>SJ</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Role of type I interferon signaling in human metapneumovirus pathogenesis and control of viral replication</article-title>. <source>J Virol</source> (<year>2015</year>) <volume>89</volume>:<fpage>4405</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1128/JVI.03275-14</pub-id><?supplied-pmid 25653440?><pub-id pub-id-type="pmid">25653440</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duerr</surname><given-names>CU</given-names></name><name><surname>McCarthy</surname><given-names>CDA</given-names></name><name><surname>Mindt</surname><given-names>BC</given-names></name><name><surname>Rubio</surname><given-names>M</given-names></name><name><surname>Meli</surname><given-names>AP</given-names></name><name><surname>Pothlichet</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Type I interferon restricts type 2 immunopathology through the regulation of group 2 innate lymphoid cells</article-title>. <source>Nat Immunol</source> (<year>2016</year>) <volume>17</volume>:<fpage>65</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1038/ni.3308</pub-id><?supplied-pmid 26595887?><pub-id pub-id-type="pmid">26595887</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haeberle</surname><given-names>HA</given-names></name><name><surname>Takizawa</surname><given-names>R</given-names></name><name><surname>Casola</surname><given-names>A</given-names></name><name><surname>Brasier</surname><given-names>AR</given-names></name><name><surname>Dieterich</surname><given-names>H-J</given-names></name><name><surname>van Rooijen</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways</article-title>. <source>J Infect Dis</source> (<year>2002</year>) <volume>186</volume>:<fpage>1199</fpage>&#x02013;<lpage>206</lpage>.<pub-id pub-id-type="doi">10.1086/344644</pub-id><?supplied-pmid 12402188?><pub-id pub-id-type="pmid">12402188</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stifter</surname><given-names>SA</given-names></name><name><surname>Bhattacharyya</surname><given-names>N</given-names></name><name><surname>Pillay</surname><given-names>R</given-names></name><name><surname>Fl&#x000f3;rido</surname><given-names>M</given-names></name><name><surname>Triccas</surname><given-names>JA</given-names></name><name><surname>Britton</surname><given-names>WJ</given-names></name><etal/></person-group>
<article-title>Functional interplay between type I and II interferons is essential to limit influenza A virus-induced tissue inflammation</article-title>. <source>PLoS Pathog</source> (<year>2016</year>) <volume>12</volume>:<fpage>e1005378</fpage>.<pub-id pub-id-type="doi">10.1371/journal.ppat.1005378</pub-id><?supplied-pmid 26731100?><pub-id pub-id-type="pmid">26731100</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermesh</surname><given-names>T</given-names></name><name><surname>Moltedo</surname><given-names>B</given-names></name><name><surname>Moran</surname><given-names>TM</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>CB</given-names></name></person-group>. <article-title>Antiviral instruction of bone marrow leukocytes during respiratory viral infections</article-title>. <source>Cell Host Microbe</source> (<year>2010</year>) <volume>7</volume>:<fpage>343</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1016/j.chom.2010.04.006</pub-id><?supplied-pmid 20478536?><pub-id pub-id-type="pmid">20478536</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohlmeier</surname><given-names>JE</given-names></name><name><surname>Cookenham</surname><given-names>T</given-names></name><name><surname>Roberts</surname><given-names>AD</given-names></name><name><surname>Miller</surname><given-names>SC</given-names></name><name><surname>Woodland</surname><given-names>DL</given-names></name></person-group>. <article-title>Type I interferons regulate cytolytic activity of memory CD8(+) T cells in the lung airways during respiratory virus challenge</article-title>. <source>Immunity</source> (<year>2010</year>) <volume>33</volume>:<fpage>96</fpage>&#x02013;<lpage>105</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2010.06.016</pub-id><?supplied-pmid 20637658?><pub-id pub-id-type="pmid">20637658</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Wright</surname><given-names>J</given-names></name><name><surname>Braciale</surname><given-names>TJ</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name></person-group>
<article-title>Type I IFN signaling facilitates the development of IL-10-producing effector CD8(+) T cells during murine influenza virus infection</article-title>. <source>Eur J Immunol</source> (<year>2016</year>) <volume>46</volume>(<issue>12</issue>):<fpage>2778</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201646548</pub-id><pub-id pub-id-type="pmid">27701741</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNally</surname><given-names>B</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Willette</surname><given-names>M</given-names></name><name><surname>Fla&#x000f1;o</surname><given-names>E</given-names></name></person-group>. <article-title>Local blockade of epithelial PDL-1 in the airways enhances T cell function and viral clearance during influenza virus infection</article-title>. <source>J Virol</source> (<year>2013</year>) <volume>87</volume>:<fpage>12916</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1128/JVI.02423-13</pub-id><?supplied-pmid 24067957?><pub-id pub-id-type="pmid">24067957</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaperot</surname><given-names>L</given-names></name><name><surname>Blum</surname><given-names>A</given-names></name><name><surname>Manches</surname><given-names>O</given-names></name><name><surname>Lui</surname><given-names>G</given-names></name><name><surname>Angel</surname><given-names>J</given-names></name><name><surname>Molens</surname><given-names>J-P</given-names></name><etal/></person-group>
<article-title>Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells</article-title>. <source>J Immunol</source> (<year>2006</year>) <volume>176</volume>:<fpage>248</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.176.1.248</pub-id><?supplied-pmid 16365416?><pub-id pub-id-type="pmid">16365416</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herold</surname><given-names>S</given-names></name><name><surname>Steinmueller</surname><given-names>M</given-names></name><name><surname>Wulffen von</surname><given-names>W</given-names></name><name><surname>Cakarova</surname><given-names>L</given-names></name><name><surname>Pinto</surname><given-names>R</given-names></name><name><surname>Pleschka</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand</article-title>. <source>J Exp Med</source> (<year>2008</year>) <volume>205</volume>:<fpage>3065</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20080201</pub-id><pub-id pub-id-type="pmid">19064696</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>D</given-names></name><name><surname>Prince</surname><given-names>A</given-names></name></person-group>. <article-title><italic>Staphylococcus aureus</italic> induces type I IFN signaling in dendritic cells via TLR9</article-title>. <source>J Immunol</source> (<year>2012</year>) <volume>189</volume>:<fpage>4040</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1201055</pub-id><?supplied-pmid 22962685?><pub-id pub-id-type="pmid">22962685</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Joyee</surname><given-names>AG</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Type I IFNs enhance susceptibility to <italic>Chlamydia muridarum</italic> lung infection by enhancing apoptosis of local macrophages</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>181</volume>:<fpage>2092</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.181.3.2092</pub-id><?supplied-pmid 18641348?><pub-id pub-id-type="pmid">18641348</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorhoi</surname><given-names>A</given-names></name><name><surname>Yeremeev</surname><given-names>V</given-names></name><name><surname>Nouailles</surname><given-names>G</given-names></name><name><surname>Weiner</surname><given-names>J</given-names><suffix>III</suffix></name><name><surname>J&#x000f6;rg</surname><given-names>S</given-names></name><name><surname>Heinemann</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics</article-title>. <source>Eur J Immunol</source> (<year>2014</year>) <volume>44</volume>:<fpage>2380</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201344219</pub-id><?supplied-pmid 24782112?><pub-id pub-id-type="pmid">24782112</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>MPR</given-names></name><name><surname>Graham</surname><given-names>CM</given-names></name><name><surname>McNab</surname><given-names>FW</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Bloch</surname><given-names>SAA</given-names></name><name><surname>Oni</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis</article-title>. <source>Nature</source> (<year>2010</year>) <volume>466</volume>:<fpage>973</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1038/nature09247</pub-id><?supplied-pmid 20725040?><pub-id pub-id-type="pmid">20725040</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer-Barber</surname><given-names>KD</given-names></name><name><surname>Andrade</surname><given-names>BB</given-names></name><name><surname>Oland</surname><given-names>SD</given-names></name><name><surname>Amaral</surname><given-names>EP</given-names></name><name><surname>Barber</surname><given-names>DL</given-names></name><name><surname>Gonzales</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk</article-title>. <source>Nature</source> (<year>2014</year>) <volume>522</volume>:<fpage>99</fpage>&#x02013;<lpage>103</lpage>.<pub-id pub-id-type="doi">10.1038/nature13489</pub-id><?supplied-pmid 24990750?><pub-id pub-id-type="pmid">24990750</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>CE</given-names></name><name><surname>Harvey</surname><given-names>RM</given-names></name><name><surname>Plumptre</surname><given-names>CD</given-names></name><name><surname>Paton</surname><given-names>JC</given-names></name></person-group>
<article-title>Development of primary invasive pneumococcal disease caused by serotype 1 pneumococci is driven by early increased type I interferon response in the lung</article-title>. <source>Infect Immun</source> (<year>2014</year>) <volume>82</volume>:<fpage>3919</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1128/IAI.02067-14</pub-id><pub-id pub-id-type="pmid">25001606</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeMessurier</surname><given-names>KS</given-names></name><name><surname>H&#x000e4;cker</surname><given-names>H</given-names></name><name><surname>Chi</surname><given-names>L</given-names></name><name><surname>Tuomanen</surname><given-names>E</given-names></name><name><surname>Redecke</surname><given-names>V</given-names></name></person-group>. <article-title>Type I interferon protects against pneumococcal invasive disease by inhibiting bacterial transmigration across the lung</article-title>. <source>PLoS Pathog</source> (<year>2013</year>) <volume>9</volume>:<fpage>e1003727</fpage>.<pub-id pub-id-type="doi">10.1371/journal.ppat.1003727</pub-id><?supplied-pmid 24244159?><pub-id pub-id-type="pmid">24244159</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Robinson</surname><given-names>KM</given-names></name><name><surname>McHugh</surname><given-names>KJ</given-names></name><name><surname>Scheller</surname><given-names>EV</given-names></name><name><surname>Mandalapu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Influenza-induced type I interferon enhances susceptibility to gram-negative and gram-positive bacterial pneumonia in mice</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source> (<year>2015</year>) <volume>309</volume>:<fpage>L158</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="doi">10.1152/ajplung.00338.2014</pub-id><?supplied-pmid 26001778?><pub-id pub-id-type="pmid">26001778</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>GT</given-names></name><name><surname>Davidson</surname><given-names>S</given-names></name><name><surname>Crotta</surname><given-names>S</given-names></name><name><surname>Branzk</surname><given-names>N</given-names></name><name><surname>Papayannopoulos</surname><given-names>V</given-names></name><name><surname>Wack</surname><given-names>A</given-names></name></person-group>. <article-title>TRAIL+ monocytes and monocyte-related cells cause lung damage and thereby increase susceptibility to influenza-<italic>Streptococcus pneumoniae</italic> coinfection</article-title>. <source>EMBO Rep</source> (<year>2015</year>) <volume>16</volume>:<fpage>1203</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="doi">10.15252/embr.201540473</pub-id><?supplied-pmid 26265006?><pub-id pub-id-type="pmid">26265006</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Moltedo</surname><given-names>B</given-names></name><name><surname>Moran</surname><given-names>TM</given-names></name></person-group>
<article-title>Type I interferon induction during influenza virus infection increases susceptibility to secondary <italic>Streptococcus pneumoniae</italic> infection by negative regulation of &#x003b3;d T cells</article-title>. <source>J Virol</source> (<year>2012</year>) <volume>86</volume>:<fpage>12304</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1128/JVI.01269-12</pub-id><pub-id pub-id-type="pmid">22951826</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahangian</surname><given-names>A</given-names></name><name><surname>Chow</surname><given-names>EK</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Kang</surname><given-names>JR</given-names></name><name><surname>Ghaffari</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>SY</given-names></name><etal/></person-group>
<article-title>Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice</article-title>. <source>J Clin Invest</source> (<year>2009</year>) <volume>119</volume>:<fpage>1910</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1172/JCI35412</pub-id><?supplied-pmid 19487810?><pub-id pub-id-type="pmid">19487810</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schliehe</surname><given-names>C</given-names></name><name><surname>Flynn</surname><given-names>EK</given-names></name><name><surname>Vilagos</surname><given-names>B</given-names></name><name><surname>Richson</surname><given-names>U</given-names></name><name><surname>Swaminathan</surname><given-names>S</given-names></name><name><surname>Bosnjak</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>The methyltransferase Setdb2 mediates virus-induced susceptibility to bacterial superinfection</article-title>. <source>Nat Immunol</source> (<year>2015</year>) <volume>16</volume>:<fpage>67</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1038/ni.3046</pub-id><?supplied-pmid 25419628?><pub-id pub-id-type="pmid">25419628</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redford</surname><given-names>PS</given-names></name><name><surname>Mayer-Barber</surname><given-names>KD</given-names></name><name><surname>McNab</surname><given-names>FW</given-names></name><name><surname>Stavropoulos</surname><given-names>E</given-names></name><name><surname>Wack</surname><given-names>A</given-names></name><name><surname>Sher</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Influenza A virus impairs control of <italic>Mycobacterium tuberculosis</italic> coinfection through a type I interferon receptor-dependent pathway</article-title>. <source>J Infect Dis</source> (<year>2014</year>) <volume>209</volume>:<fpage>270</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1093/infdis/jit424</pub-id><?supplied-pmid 23935205?><pub-id pub-id-type="pmid">23935205</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guarda</surname><given-names>G</given-names></name><name><surname>Braun</surname><given-names>M</given-names></name><name><surname>Staehli</surname><given-names>F</given-names></name><name><surname>Tardivel</surname><given-names>A</given-names></name><name><surname>Mattmann</surname><given-names>C</given-names></name><name><surname>F&#x000f6;rster</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Type I interferon inhibits interleukin-1 production and inflammasome activation</article-title>. <source>Immunity</source> (<year>2011</year>) <volume>34</volume>:<fpage>213</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2011.02.006</pub-id><?supplied-pmid 21349431?><pub-id pub-id-type="pmid">21349431</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meissner</surname><given-names>NN</given-names></name><name><surname>Swain</surname><given-names>S</given-names></name><name><surname>Tighe</surname><given-names>M</given-names></name><name><surname>Harmsen</surname><given-names>A</given-names></name><name><surname>Harmsen</surname><given-names>A</given-names></name></person-group>. <article-title>Role of type I IFNs in pulmonary complications of <italic>Pneumocystis murina</italic> infection</article-title>. <source>J Immunol</source> (<year>2005</year>) <volume>174</volume>:<fpage>5462</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.174.9.5462</pub-id><?supplied-pmid 15843544?><pub-id pub-id-type="pmid">15843544</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>I</given-names></name><name><surname>Miyasaka</surname><given-names>T</given-names></name><name><surname>Zong</surname><given-names>T</given-names></name><etal/></person-group>
<article-title><italic>Cryptococcus neoformans</italic> infection in mice lacking type I interferon signaling leads to increased fungal clearance and IL-4-dependent mucin production in the lungs</article-title>. <source>PLoS One</source> (<year>2015</year>) <volume>10</volume>:<fpage>e0138291</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0138291</pub-id><?supplied-pmid 26384031?><pub-id pub-id-type="pmid">26384031</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biondo</surname><given-names>C</given-names></name><name><surname>Midiri</surname><given-names>A</given-names></name><name><surname>Gambuzza</surname><given-names>M</given-names></name><name><surname>Gerace</surname><given-names>E</given-names></name><name><surname>Falduto</surname><given-names>M</given-names></name><name><surname>Galbo</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>IFN-alpha/beta signaling is required for polarization of cytokine responses toward a protective type 1 pattern during experimental cryptococcosis</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>181</volume>:<fpage>566</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.181.1.566</pub-id><?supplied-pmid 18566423?><pub-id pub-id-type="pmid">18566423</pub-id></mixed-citation></ref></ref-list></back></article>